About elobixibat(Nonproprietary name
: elobixibat hydrate; development code AJG533; brand name "GOOFICE 5 mg Tablet")
Some people have voiced concern that it would be better for names to have some meaning, such as using an abbreviated name for the developing company along with the nonproprietary name
of the originator product, but others noted that method could be problematic when companies merge or are acquired by others.
(64) These natural variations undercut any theoretical justification for a different biosimilar nonproprietary name
, as these biosimilars merely demonstrate slight variations not unlike differences between original biologics batches.
Fidanacogene elaparvovec is the official US adopted name and will become the recommended international nonproprietary name
for the therapy formerly known as SPK-9001 and PF-06838435.
announce that an oral presentation on PIII clinical study data on "GOOFICE 5mg Tablet" (nonproprietary name
: elobixibat hydrate; development code: AJG533, hereinafter "elobixibat"), a bile acid transporter inhibitor launched in Japan on April 19, 2018, will be given at Digestive Disease Week (DDW) 2018, June 2-5 in Washington D.C., USA.
This effect, however, would be minimized if interchangeable biologies share the same nonproprietary name
as the reference biologies, said JMCP, which is the official scientific journal of the Academy of Managed Care Pharmacy (AMCP).
M2 EQUITYBITES-December 11, 2014-Ignyta receives approval from World Health Organisation for using Nonproprietary name
'entrectinib' for RXDX-101
The typical entry, titled according to international nonproprietary name
, opens by listing chemical name, Anatomical Therapeutic Chemical Code, major uses, Chemical Abstracts Service numbers, molecular formula (using the Hill System), and weight.
today announced that the bile acid transporter inhibitor "GOOFICE 5mg Tablet" (nonproprietary name
: elobixibat hydrate; development code: AJG533) was listed in Japan's National Health Insurance Drug Price List as of April 18, 2018, and EA Pharma and Mochida launched the product onto Japan's market today.
M2 EQUITYBITES-February 21, 2013-NovaBay Pharmaceuticals Inc's international nonproprietary name
auriclosene for NVC-422 approved by WHO(C)2013 M2 COMMUNICATIONS http://www.m2.com